摘要
目的观察和探讨甲状腺全切术结合131Ⅰ清甲治疗甲状腺嗜酸细胞肿瘤(HCT)的临床疗效及安全性。方法将2003年1月至2013年1月期间收治的25例HCT患者作为研究对象。患者行甲状腺癌全切术和131Ⅰ清甲治疗,观察治疗后并发症及甲状旁腺功能减退发生情况,并根据131Ⅰ显像及Tg含量检测结果进行疗效评定,随访1年,观察肿瘤复发情况。结果所有患者术后无声嘶、感染等并发症,1例术后出现手足麻木。治疗总有效率为88.00%。随访1年期间复查颈部B超,未见甲状腺床及颈部淋巴结异常肿大,也未见甲状旁腺功能持续性减退。结论甲状腺全切术结合131Ⅰ清甲治疗HCT,疗效满意,安全性高,中远期疗效仍有待进一步观察。
Objective To investigate the clinical effect and safety of thyroid cancer eosinophils （HCT） treated with total thyroidectomy combined with 131 I ablation therapy. Methods The 25 patients of HCT from January 2003 to January 2013 were included into this study. All these patients were considered as the observation group. All patients diagnosed after admission underwent thyroid cancer resection, postoperative 131 I ablation therapy combined with observation complications in this group of patients after treatment and the occurrence of hypoparathyroidism, and in accordance with the content of 131 I imaging and Tg test results for this group of patients assessed for efficacy, 1 - year follow - up of patients, tumor recurrence was observed. Results There was no hoarseness, infection and other complications in 25 patients. 1 patient with postop-erative numbness. The total effective rate was 88.00%. All patients were followed up for 1 year by the neck uhrasonography, no abnormal and cervical lymph nodes were found in the thyroid bed, but also no persistent parathyroid dysfunction. Conclusion The application of total thyroideetomy combined 131 I ablation therapy earl be used to treat the patients of HCT. The effieacy is satisfactory, safe. However, the long - term efficacy remains to be investigated.
出处
《临床和实验医学杂志》
2014年第11期890-892,共3页
Journal of Clinical and Experimental Medicine
